Garbe C - Search Results

1

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD. Weide B, et al. Among authors: garbe c. Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. doi: 10.1158/1078-0432.CCR-16-0127. Epub 2016 May 16. Clin Cancer Res. 2016. PMID: 27185375 Free PMC article.

2

A rational approach to the follow-up of melanoma patients.

Garbe C. Garbe C. Recent Results Cancer Res. 2002;160:205-15. doi: 10.1007/978-3-642-59410-6_24. Recent Results Cancer Res. 2002. PMID: 12079215

3

Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.

Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B, Meier F, Schittek B, Blaheta HJ, Blum A, Rassner G. Garbe C, et al. J Clin Oncol. 2003 Feb 1;21(3):520-9. doi: 10.1200/JCO.2003.01.091. J Clin Oncol. 2003. PMID: 12560444

4

Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.

Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B. Garbe C, et al. Cancer. 2003 Apr 1;97(7):1737-45. doi: 10.1002/cncr.11250. Cancer. 2003. PMID: 12655531 Free article.

5

Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma.

Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Möller H, Maczey E, Rassner G, Herlyn M, Garbe C. Meier F, et al. Among authors: garbe c. Exp Dermatol. 2003 Jun;12(3):296-306. doi: 10.1034/j.1600-0625.2003.120310.x. Exp Dermatol. 2003. PMID: 12823444

6

The natural course of cutaneous melanoma.

Leiter U, Meier F, Schittek B, Garbe C. Leiter U, et al. Among authors: garbe c. J Surg Oncol. 2004 Jul 1;86(4):172-8. doi: 10.1002/jso.20079. J Surg Oncol. 2004. PMID: 15221923 Review.

7

Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.

Eigentler TK, Buettner PG, Leiter U, Garbe C; Central Malignant Melanoma Registry of the German Dermatological Society. Eigentler TK, et al. Among authors: garbe c. J Clin Oncol. 2004 Nov 1;22(21):4376-83. doi: 10.1200/JCO.2004.03.075. J Clin Oncol. 2004. PMID: 15514379

8

Imiquimod in the treatment of extensive recurrent lentigo maligna.

Kamin A, Eigentler TK, Radny P, Bauer J, Weide B, Garbe C. Kamin A, et al. Among authors: garbe c. J Am Acad Dermatol. 2005 Feb;52(2 Suppl 1):51-2. doi: 10.1016/j.jaad.2004.07.047. J Am Acad Dermatol. 2005. PMID: 15692515

9

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G, Herlyn M. Meier F, et al. Among authors: garbe c. Front Biosci. 2005 Sep 1;10:2986-3001. doi: 10.2741/1755. Front Biosci. 2005. PMID: 15970553 Review.

10

[Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma].

Eigentler TK, Radny P, Kamin A, Weide B, Caroli UM, Garbe C. Eigentler TK, et al. Among authors: garbe c. J Dtsch Dermatol Ges. 2005 Aug;3(8):592-8. doi: 10.1111/j.1610-0387.2005.05051.x. J Dtsch Dermatol Ges. 2005. PMID: 16033477 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

787 results

Search Page